Olive Leaf Metabolic Health Randomized Trial: What the Evidence Says

Quick Answer

Olive Leaf Metabolic Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Beyond its reproductive implications, menopause is increasingly recognized as a turning point in systemic health, contributing to changes in metabolic regulation, cardiovascular risk, and connective tissue integrity. [Lasfar Anissa (2025); evidence level 2]
• For example, increased activity of matrix metalloproteinases (MMPs) indicates enhanced ECM breakdown, while the accumulation of advanced glycation end-products (AGEs) reflects oxidative stress and protein damage. [Lasfar Anissa (2025); evidence level 2]
• Major risk factors include hypercholesterolemia, hypertension, diabetes, infections, and smoking. [Morvaridzadeh Mojgan (2025); evidence level 3]
• Emerging evidence highlights a bidirectional relationship between the gut microbiota and dietary polyphenols, particularly in the modulation of inflammation and lipid metabolism; two central processes in atherosclerosis. [Morvaridzadeh Mojgan (2025); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For olive leaf metabolic health randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Lasfar Anissa (2025). Effects of olive leaf extract supplementation on systemic markers of tissue aging and remodeling in postmenopausal women: a randomized controlled trial with exploratory skin outcomes. DOI: 10.3389/fnut.2025.1670194. PMCID: PMC12671197. PMID: 41340653. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12671197/
• Morvaridzadeh Mojgan (2025). Polyphenol-Microbiota Interactions in Atherosclerosis: The Role of Hydroxytyrosol and Tyrosol in Modulating Inflammation and Oxidative Stress. DOI: 10.3390/nu17233784. PMCID: PMC12694252. PMID: 41374074. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12694252/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.